Built in Boston, now rebuilding businesses

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michael Kallelis, Chief Executive Officer at Mikart. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mike, covering: Growing up, studying and forging a career in Boston during the volatile biotech boom in Massachusetts. His hard-earned 40-years playbook of how to rebuild and revitalise a family owned business by respecting, studying and redirecting efforts. An insight into the under the radar but explosively vibrant life science scene in Atlanta, GA The role of a mid-market CDMO to drug development companies. The phenomenon hitting the North America healthcare market that you need to be aware of as it will impact CDMOs in the small molecule space... Michael Kallelis has spent his career in public and private life science companies where he has successfully implemented commercial and operational growth strategies. Prior to Mikart, he held several senior roles including president of Exiqon Inc., co-founder and chief operating officer of Boston Biosystems, vice president of business development at KMC Systems, and general manager of several GE Healthcare businesses.  His experience covers a range of technologies, including radiopharmaceuticals, gene expression analysis, medical devices, automated laboratory systems, oligonucleotides, specialty chemicals, biologics, and small molecules. Mike has been the CEO at Mikart since the fall of 2018. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.